Public Summary

Summary for ARTG Entry: 179231 Swisse Men's Ultivite 65+ Multivitamin, Mineral and Antioxidant with Herbs

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	18/01/2011
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27). This condition does not apply to powdered or dried leaf.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

Where the medicine is a conventional release folic acid supplement preparation, in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the responsibility of manufacturers to develop and validate the analytical methods for the determination of folic acid that should be used in conjunction with the USP24 dissolution criteria. This condition does not apply to chewable, effervescent or dispersible tablets or sustained release tablets.

Products

1. Swisse Men's Ultivite 65+ Multivitamin, Mineral and Antioxidant with Herbs

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

WARNING: When taken in excess of 3000 micrograms retinol equivalents, vitamin A can cause birth defects.,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

Not for the treatment of iron deficiency conditions (or words to that effect).,

Do not take while on warfarin therapy without medical advice.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.,

Helps maintain normal blood/blood tonic (Note: These claims are appropriate for folic acid, vitamin B12 and iron, but must not imply anaemic conditions),

May assist in maintaining peripheral circulation and promoting general health.,

For mineral (may state the mineral) supplementation.,

For vitamin (may state the vitamin) supplementation.,

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).,

May assist in the management of dietary folate deficiency.,

Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Specific Indications

a comprehensive formula containing premium quality vitamins, minerals, herbs and antioxidants designed to support the specific nutritional needs and health concerns of men over the age of 65.
includes over 40 essential vitamins, minerals, herbs and antioxidants to supplement the diet and support the body's nutritional needs.
includes high levels of B vitamins to help support energy production
1000IU of natural vitamin D3 per tablet to assist the absorption of calcium and help maintain healthy bone density.
contains antioxidants such as Knotweed, a source of resveratrol, and grape seed to protect cells against free radical damage. includes saw palmetto and tribulus to promote stamina and help support male health in those over 65 years of age.
may help to maintain healthy homocysteine levels.
provides support for the nervous system.

Additional Product Information

Pack Size/Poison Information

Pack Size	**Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Biotin	**200 microgram**
Calcium ascorbate dihydrate	**200 mg**
Calcium orotate	**100 mg**
Calcium pantothenate	**109.15 mg**
Cholecalciferol	**.025 mg**
Chromium picolinate	**402.3 microgram**
Citrus bioflavonoids extract	**20 mg**
Copper gluconate	**12.14 mg**
Crataegus monogyna	**30 mg**
Equivalent: Crataegus monogyna (Dry)	120 mg
Cyanocobalamin	**200 microgram**
Cynara scolymus	**1 mg**
Equivalent: Cynara scolymus (Fresh)	50 mg
d-alpha-Tocopheryl acid succinate	**25 mg**
Dulacia inopiflora	**20 mg**
Equivalent: Dulacia inopiflora (Dry)	200 mg
Fallopia japonica	**80 mg**
Equivalent: Fallopia japonica (Dry)	8 g
Ferrous fumarate	**16.01 mg**
Folic acid	**500 microgram**
Ginkgo biloba	**20 mg**
Equivalent: Ginkgo biloba (Dry)	1 g
Lecithin powder - soy phosphatidylserine-enriched soy	**10 mg**
Lutein	**1 mg**
Magnesium aspartate dihydrate	**100 mg**
Manganese amino acid chelate	**40 mg**
Molybdenum trioxide	**67.5 microgram**
Nicotinamide	**100 mg**
Phytomenadione	**70 microgram**
Potassium iodide	**196 microgram**
Pyridoxine hydrochloride	**50 mg**
Retinyl acetate	**.8625 mg**
Riboflavin	**50 mg**

Scutellaria lateriflora	**12.5 mg**
Equivalent: Scutellaria lateriflora (Dry)	50 mg
Selenomethionine	**124.2 microgram**
Serenoa repens	**75 mg**
Equivalent: Serenoa repens (Dry)	300 mg
Silybum marianum	**24.29 mg**
Equivalent: Silybum marianum (Dry)	1.7 g
Spearmint Oil	**2 mg**
Thiamine hydrochloride	**50 mg**
Tribulus terrestris	**10 mg**
Equivalent: Tribulus terrestris (Dry)	500 mg
Tribulus terrestris	**10 mg**
Equivalent: Tribulus terrestris (Dry)	500 mg
Ubidecarenone	**3 mg**
Urtica dioica	**5 mg**
Equivalent: Urtica dioica (Dry)	50 mg
Vaccinium macrocarpon	**2 mg**
Equivalent: Vaccinium macrocarpon (Fresh)	1 g
Vaccinium myrtillus	**1 mg**
Equivalent: Vaccinium myrtillus (Fresh)	100 mg
Vitis vinifera	**8.33 mg**
Equivalent: Vitis vinifera (Dry)	1 g
Zinc amino acid chelate	**100 mg**

Public Summary

Summary for ARTG Entry: 188269 Swisse Ultiboost Odourless Wild Fish Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	19/08/2011
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Odourless Wild Fish Oil

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May help increase joint mobility associated with arthritis.,

Temporary relief of the pain of arthritis. (or) Temporary relief of arthritic pain. [Warning S required],

May help reduce joint inflammation associated with arthritis.

Specific Indications

Studies show that fish oils help maintain general good health and are especially beneficial for the heart, brain, joints and eyes.
It has been shown that omega-3 fatty acids may play an important role in helping maintain a healthy cardiovascular system by supporting normal circulation, blood pressure and cholesterol in healthy individuals.
DHA is the predominant fatty acid in the central nervous system found in the walls of brain cells and is important for the natural repair process.
Omega-3 fatty acids may be beneficial for joint health and are vital for vision. They play a structural and functional role in the retina and nerve cells of the eye.
Swisse Ultiboost Odourless Wild Fish Oil contains premium ingredients. It contains omega-3 fatty acids, EPA and DHA and is sourced from wild fish that swim freely in the Pacific Ocean ± 'sustainable free range fish'.
Swisse Ultiboost Odourless Wild Fish Oil capsules are completely free from 'fishy' taste or smell and contain added natural spearmint oil and vanilla flavour.
Based on 25+ years research.
You'll feel better on Swisse.
Does not contain artificial chemicals such as polysorbate to reduce the reflux action and fishy after taste.

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
Components	
1. Formulation 1	
Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Fish oil - natural	**1000 mg**

Public Summary

Summary for ARTG Entry: 187006 Swisse Ultiboost Prostate

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	29/07/2011
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

Where the medicine is a conventional release folic acid supplement preparation, in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the responsibility of manufacturers to develop and validate the analytical methods for the determination of folic acid that should be used in conjunction with the USP24 dissolution criteria. This condition does not apply to chewable, effervescent or dispersible tablets or sustained release tablets.,

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

Products

1. Swisse Ultiboost Prostate

Product Type Single Medicine Product **Effective date** 22/01/2013

Warnings

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

May assist in the management of medically diagnosed benign prostatic hypertrophy.,

Aids, assists or helps in the maintenance or improvement of general well-being.,

For the symptomatic relief of medically diagnosed benign prostatic hypertrophy.

Specific Indications

Swisse Ultiboost Prostate is based on over 25 years of research and contains premium quality ingredients to assist in normal prostate function. Certain ingredients in the formula may provide relief from the symptoms of medically diagnosed Benign Prostatic Hypertrophy (or Hyperplasia, commonly known as prostate enlargement), including difficulties in micturition, a hesitant interrupted weak stream, urinary frequency, urgency and dribbling or leaking.

Additional Product Information

Pack Size/Poison information

Pack Size	**Poison Schedule**
Components	
1. Formulation 1	
Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Cholecalciferol	**1.25 microgram**
Cucurbita pepo	**25 mg**
Equivalent: Cucurbita pepo (Dry)	500 mg
Curcuma longa	**25 mg**
Folic acid	**250 microgram**
Ganoderma lucidum	**2.75 mg**
Equivalent: Ganoderma lucidum (Dry)	55 mg
Glycyrrhiza glabra	**13.75 mg**
Equivalent: Glycyrrhiza glabra (Dry)	55 mg
Isatis tinctoria	**11 mg**
Equivalent: Isatis tinctoria (Dry)	55 mg
Lycopersicon esculentum	**10 mg**
Panax ginseng	**5.5 mg**
Equivalent: Panax ginseng (Dry)	55 mg
Selenomethionine	**16.25 microgram**
Serenoa repens	**217.5 mg**
Equivalent: Serenoa repens (Dry)	870 mg
Serenoa repens	**100 mg**
Equivalent: Serenoa repens (Dry)	1 g
Urtica dioica	**62.5 mg**
Equivalent: Urtica dioica (Dry)	1 g
Zinc amino acid chelate	**30 mg**

Public Summary

Summary for ARTG Entry: 186097 Swisse Magnesium

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	30/06/2011
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Magnesium

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Specific Indications

For magnesium supplementation.

Additional Product Information

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Magnesium citrate	**927.64 mg**

Public Summary

Summary for ARTG Entry: 181937 Swisse Professional Green Tea Extract

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	7/04/2011
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Professional Green Tea Extract

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] [must be clear and legible].

Standard Indications

Specific Indications

Swisse Professional Green Tea is a concentrated extract with potent antioxidant properties to support the cardiovascular system and maintain a healthy metabolism.
The therapeutic properties of green tea can be attributed to certain antioxidant compounds, known as catechins, for which green tea is a rich source. The green tea extract in Swisse Professional Green Tea is standardised to ensure the potency of catechins in every tablet for antioxidant defence against free radical damage.
Swisse Professional Green Tea uses young tea leaves, cultivated delicately and harvested at selected times to target naturally occurring and therapeutically active components within the plant.
Green tea is a rich source of antioxidant catechins.
Antioxidants defend against free radical damage.

Additional Product Information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral

Visual Identification

Active Ingredients

Camellia sinensis	**972 mg**
Equivalent: Camellia sinensis (Dry)	24.3 g

Public Summary

Summary for ARTG Entry: 186092 Swisse Calcium + Vitamin D

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	30/06/2011
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

Products

1. Swisse Calcium + Vitamin D

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Specific Indications

For calcium and vitamin D supplementation.

Additional Product Information

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Calcium citrate	**1.579 g**
Cholecalciferol	**.0083 mg**

Public Summary

Public Summary

Summary for ARTG Entry: 193883 Swisse Practitioner Yeast Response

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	17/01/2012
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

Products

1. Swisse Practitioner Yeast Response

Product Type Single Medicine Product **Effective date** 19/01/2012 3:07:27 PM

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Specific Indications

Swisse Practitioner Yeast Response is a premium quality herbal and nutritional formula which provides support in the maintenance of normal intestinal Candida levels, helps to restore microflora balance and supports the integrity of the digestive lining.
The therapeutic properties of this formula can be attributed to golden seal, Pau D'arco, Oregon grape and calendula, which have traditionally been used to support the immune system.
It also contains biotin to help supplement any loss of natural biotin production due to microflora imbalance.
This combination of herbs from traditional Western herbal medicine may help protect against fungal and other microbial infections.
The herbs in Swisse Practitioner Yeast Response have been traditionally used in the herbal medicine of the Americas for fighting infections. The herbs have shown antimicrobial activity and have been traditionally used for their beneficial effect on the body's mucous membranes and digestive ability to assist in restoring normal microflora.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Berberis aquifolium	**150 mg**
Equivalent: Berberis aquifolium (Dry)	600 mg
Biotin	**33.33 mg**
Calendula officinalis	**250 mg**
Equivalent: Calendula officinalis (Dry)	1 g
Hydrastis canadensis	**83.33 mg**
Equivalent: Hydrastis canadensis (Dry)	333.32 mg
Tabebuia avellanedae	**208.33 mg**
Equivalent: Tabebuia avellanedae (Dry)	833.32 mg
Zinc amino acid chelate	**16.67 mg**

Public Summary

Summary for ARTG Entry: 169265 Swisse Ultiboost Super C

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	19/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Super C

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Do not take while on warfarin therapy without medical advice.,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).

Standard Indications

May help reduce the severity of the symptoms of colds.]Warnings S and COLD required],

May reduce the severity and duration of colds. [Warning COLD required]

Specific Indications

Swisse Ultiboost products are based on the assessment of clinical studies and incorporate highest grade, scientifically validated ingredients which have been proven to deliver results.
Benefits Swisse Ultiboost Super C is based on 25 years of research and contains scientifically validated ingredients to help reduce the severity and duration of colds and support the body?s normal resistance to colds and flu. Vitamin C is a potent antioxidant which can help reduce the risk of cell damage from free radicals. Vitamin C also helps to enhance the absorption of dietary iron and may help promote skin health and wound healing because of its involvement in the manufacture of collagen.
Swisse Ultiboost Super C is derived from non acidic calcium ascorbate making it gentle on the stomach.
-antioxidant, helps to reduce free radical damage
-may help to boost your immune system
-traditionally, vitamin c may help to reduce histamine levels, helping in the management of some allergies
- vitamin c may help improve normal, healthy immune function
- vitamin c is water soluble and is not stored in the body, therefore regular/daily intake is desirable

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions

Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Calcium ascorbate dihydrate	**1.2478 g**
Ubidecarenone	**.999 mg**

Public Summary

Summary for ARTG Entry: 174560 Swisse Ultiboost Wild Fish Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	5/08/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Wild Fish Oil

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Symptomatic relief of osteoarthritis. [Warning S required],

May assist in the management of osteoarthritis. [Warning S required],

May help increase joint mobility associated with arthritis.,

May help reduce joint inflammation associated with arthritis.

Specific Indications

Studies show that fish oils help maintain general good health and are especially beneficial for the heart, brain, joints and eyes.
It has been shown that omega-3 fatty acids may play an important role in helping maintain a healthy cardiovascular system by supporting normal circulation, blood pressure and cholesterol in healthy individuals.
DHA is the predominant fatty acid in the central nervous system found in the walls of brain cells and is important for the natural repair process.
Omega-3 fatty acids may be beneficial for joint health and are vital for vision. They play a structural and functional role in the retina and nerve cells of the eye.
Swisse Ultiboost Wild Fish Oil contains premium ingredients. It contains omega-3 fatty acids, EPA and DHA and is sourced from wild fish that swim freely in the Pacific Ocean ± 'sustainable free range fish'.
you'll feel better on swisse
Based on 25+ years research

Additional Product information

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Fish oil - natural	**1000 mg**

Public Summary

Summary for ARTG Entry: 169764 Swisse Ultiboost Executive Focus

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	11/03/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27). This condition does not apply to powdered or dried leaf.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Executive Focus

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids or assists in the maintenance of peripheral circulation.

Specific Indications

Swisse Ultiboost EXECUTIVE FOCUS is based on 25 years of research and contains scientifically validated ingredients to assist in memory function and stamina. Swisse Ultiboost EXECUTIVE FOCUS is based on the assessment of clinical studies that show certain ingredients in the formula can improve short-term memory, enhance mental alertness, help to relieve anxiety and stress. Swisse Ultiboost EXECUTIVE FOCUS helps to improve brain functions such as learning and concentration. Used as directed, Swisse Ultiboost EXECUTIVE FOCUS may deliver positive results relatively quickly.
If you suffer from any medical conditions, please consult your health care professional for advice on the suitability of this product for you. Use only as directed and see your health care professional if symptoms persist.
Vitamin supplements should not replace a balanced diet.

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Bacopa monnieri	**186.66 mg**
Calcium pantothenate	**70 mg**
Cyanocobalamin	**25 microgram**
Ginkgo biloba	**60 mg**
Equivalent: Ginkgo biloba (Dry)	3 g
Nicotinamide	**20 mg**
Pyridoxine hydrochloride	**25 mg**
Riboflavin	**35 mg**
Thiamine	**25 mg**

Public Summary

Summary for ARTG Entry: 169032 Swisse Women's Green Ultivite

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	12/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Women's Green Ultivite

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

The recommended dose of this medicine provides small amounts of caffeine

Standard Indications

Specific Indications

Swisse Women?s Green Ultivite is based on over 25 years of research
maintain general wellbeing
trace vitamin and mineral supplement
contains phytonutrient rich spirulina
contains antioxidant rich herbs

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Arthrospira platensis	**500 mg**
Camellia sinensis	**6.25 mg**

Mentha X piperita	**20 mg**
Olea europaea	**10 mg**
Equivalent: Olea europaea (Dry)	100 mg
Punica granatum	**2 mg**
Equivalent: Punica granatum (Dry)	100 mg
Silybum marianum	**14.29 mg**
Equivalent: Silybum marianum (Dry)	1000 mg
Vitex agnus-castus	**10 mg**
Equivalent: Vitex agnus-castus (Dry)	100 mg
Withania somnifera	**10 mg**
Equivalent: Withania somnifera (Dry)	100 mg

Public Summary

Summary for ARTG Entry: 169030 Swisse Ultiboost Calcium + Vitamin D

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	12/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Calcium + Vitamin D

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Source of calcium. Women's calcium requirements are increased after menopause. Calcium supplementation may be of assistance in the prevention and/or treatment of osteoporosis.,

Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life,

Source of calcium. Women's calcium requirements are increased after menopause.,

Source of calcium. A calcium supplement formulated to strengthen bone and tissue in growing and mature users. (or) Source of calcium. A calcium supplement formulated to strengthen bone and tissue for children and older adults.,

Source of calcium. Adequate dietary calcium in our youth and throughout life is required to maximise bone.,

Source of calcium. May assist in the prevention and/or treatment of osteoporosis.

Specific Indications

Vitamin D3 and calcium supplement for when these vitamins/minerals are lacking in the diet
Vitamin D supplementation may assist in regulation of calcium metbolism and bone mineralization in those not obtaining sufficient vitamin D due to diet or lifestyle factors
Vitamin D promotes the body?s absorption of calcium, important to maintain healthy bones and teeth
A supplement to aid in the management of calcium deficiency states
Helps maintain healthy bones and teeth
Calcium requirements may be increased with age, gender, diet, pregnancy and laction ? provides supplemental calcium
Women?s calcium needs are increased after menopause
Formulated using the citrate form of calcium, shown to have a higher bioavailability than other forms of calcium
Patented black pepper extract (piper nigrum) Bioperine contains active ingredient piperine, shown to help increase nutrient uptake

Additional Product information

Pack Size/Poison information

Pack Size	**Poison Schedule**
Components	
1. Formulation 1	
Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Calcium citrate	**1.5798 g**
Cholecalciferol	**.0083 mg**
Piper nigrum	**1.75 mg**
Equivalent: Piper nigrum (Dry)	29.75 mg

Public Summary

Summary for ARTG Entry: 168788 Swisse Ultiboost Sports

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	4/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Sports

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

L-carnitine is responsible for the transport of long-chain fatty acids into the energy producing units in cells, the mitochondria.
A deficiency in l-carnitine results in decreased fatty acid concentrations in the mitochondria and as a result, reduced energy production.
l-carnitine may improve the utilisation of fat as an energy source. Therefore, l-carnitine may be beneficial for a variety of conditions associated with impaired fat utilisation and energy production.
A skeletal muscle carnitine deficiency may be associated with impairment of muscle function
Tribulus has a long history of use as a physical rejuvenation tonic. It may help maintain general wellbeing and physical vitality for both men and women, and be beneficial as a nervous system tonic herb during times of stress.
The use of Siberian ginseng in China and Russia dates back several thousands of years. Traditionally it has been used to help the body adapt when under physical and mental stress.
Siberian ginseng is an adaptogenic herb traditionally used as a tonic to support the body during periods of exertion. Also useful during convalescence

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Eleutherococcus senticosus	**16.67 mg**
Equivalent: Eleutherococcus senticosus (Dry)	250 mg
Levocarnitine	**500 mg**
Tribulus terrestris	**25 mg**
Equivalent: Tribulus terrestris (Fresh)	1.25 g
Tribulus terrestris	**25 mg**
Equivalent: Tribulus terrestris (Dry)	1.25 g

Public Summary

Summary for ARTG Entry: 168781 Swisse Ultiboost Glucosamine +

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	4/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Glucosamine +

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Derived from seafood.,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May help reduce joint inflammation associated with arthritis.,

May help reduce joint swelling associated with arthritis.,

May help increase joint mobility associated with arthritis.,

Symptomatic relief of osteoarthritis. [Warning S required]

Specific Indications

Ginger is included - long history has been used in traditional Chinese and Ayurvedic medicine for thousands of years for its anti-inflammatory properties, it also helps blood flow and delivery of nutritents to the joints

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form Tablet, film coated

Route of Administration	Oral	
Visual Identification		
Active Ingredients		
Glucosamine sulfate-sodium chloride complex		**1.8858 g**
Zingiber officinale		**25 mg**
Equivalent: Zingiber officinale (Fresh)		500 mg

Public Summary

Summary for ARTG Entry: 168786 Swisse Ultiboost Complete Natural Vitamin E

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	4/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Complete Natural Vitamin E

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Specific Indications

Prevention/treatment of dietary vitamin E deficiency
Antioxidant properties
Contains naturally sourced mixed tocotrienols.
Helps to support heart/cardiovascular health
Swisse Ultiboost Complete Natural Vitamin E contains premium quality ingredients to help support heart health and circulation. Swisse Ultiboost Complete Natural Vitamin E contains natural vitamin E which is retained for a longer period in the blood compared to synthetic forms. The formula supports heart health and assists with blood circulation. It also acts as an antioxidant to protect cells from potential free radical damage.
You'll feel better on Swisse.
Based on 25+ years research.

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients

d-alpha-Tocopherol	**335.6 mg**
Tocotrienols complex - palm	**2 mg**

Public Summary

Summary for ARTG Entry: 175898 Swisse Ultiboost Appetite Suppressant

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	17/09/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Appetite Suppressant

Product Type Single Medicine Product **Effective date** 4/04/2013

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

may assist/help/aid in appetite suppression in healthy individuals
an appetite suppressant for helping to control appetite, based on traditional evidence.
Slimaluma (Caralluma adscendens var. fimbriata) is an edible plant used for centuries in India as a famine food and appetite suppressant.
Succulent edible cactus that grows freely all over India.
Traditionally tribal people are reported to eat the cactus when hunting or embarking on a long journey as it can suppress the appetite for several hours.
This product is not intended for use as a weight loss product.
You'll feel better on Swisse.
Contains premium quality ingredients
Best combined with healthy eating/healthy diet and as part of a regular exercise regime/exercise

Additional Product Information

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Caralluma adscendens var. fimbriata	**500 mg**

Equivalent: Caralluma adscendens var. fimbriata (Dry)	6 g

Public Summary

Summary for ARTG Entry: 175334 Swisse Ultiboost Inner Balance

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	2/09/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Inner Balance

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

· Contributes {Participates} {Helps} to {strengthen} your body's natural defenses
· {Supports} the body's immune {system} {function}
· {Boosts} {Strengthens} {Modulates} your body's natural defenses
· Naturally {boosts} {strengthens} your body's defenses
· Helps support a healthy immune {system} {function}
· Enhances infection resistance
· Scientifically shown to support natural killer cell activity, a critical component of the natural immune function.

Gut Health Indications:
· Maintains {balance} {levels} of healthy {cultures} {bacteria} {flora}
· supports levels of beneficial microflora
· Shown to be antagonistic to GI pathogens, known risk factors in human disease
· Supports good digestive function
· Helps maintain a microbial balance that is associated with good digestive health
· Helps maintain a healthy digestive system
· Aids in the digestion of dairy products

Swisse Ultiboost Inner Balance contains premium quality probiotic strains to help support intestinal health, digestive function and inner wellbeing.
Probiotics are friendly bacteria that live naturally in the gut. Studies show that probiotics help maintain a balanced intestinal and digestive environment, which results in healthy digestion, regular bowel function and general wellbeing.
Swisse Ultiboost Inner Balance contains Danisco HOWARU® bifido, a clinically tested strain of probiotic scientifically shown to strengthen the body's natural defences and help support a healthy immune system. HOWARU® bifido has been carefully selected for its ability to survive the digestive processes.
If you have been taking a course of antibiotics, friendly bacteria levels in the digestive system may be disrupted. Swisse Ultiboost Inner Balance can balance levels of friendly bacteria that
may have been interrupted due to antibiotic use. Probiotics are sensitive to temperature.
Swisse Ultiboost Inner Balance should be refrigerated to ensure stability and potency.

Additional Product information

Pack Size/Poison information

Pack Size	**Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	

Active Ingredients

Bifidobacterium lactis	**8.335 mg**
Bifidobacterium lactis	**11.665 mg**
Lactobacillus acidophilus	**26.25 mg**

Public Summary

Summary for ARTG Entry: 174637 Swisse Pregnancy + Ultivite

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	7/08/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Pregnancy + Ultivite

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Not for the treatment of iron deficiency conditions (or words to that effect).,

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

Do not exceed the stated dose except on medical advice. If you have had a baby with a neural tube defect/spina bifida, seek specific medical advice (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

Swisse Pregnancy + Ultivite contains premium quality ingredients to provide nutritional support for mother and baby during preconception, pregnancy and breastfeeding.
One-a-day multivitamin and omega-3 DHA supplement designed to safeguard nutritional intake and the increased physiological demands on the mother's body during pregnancy.
The benefits of taking Omega-3 DHA during pregnancy have been well researched, as the growing baby relies solely on supplies from the mother.
Omega-3 DHA plays an essential role in the healthy development of the brain, nervous system and eyes in the foetus and newborn.
Includes iodine to promote baby's healthy brain development during pregnancy and lactation.
Swisse Pregnancy + Ultivite also contains the recommended amount of folic acid, which may reduce the risk of birth defects such as spina bifida. Folic acid is needed for the synthesis of DNA and is important in periods of rapid cell growth.
B vitamins help to support increased energy requirements during pregnancy.
Iron helps to address increased needs during pregnancy, maintain healthy blood and assist in the formation of haemoglobin, the oxygen carrier in red blood cells.
Natural vitamin D has helps to aid the absorption of calcium which is vital for the development of bones and teeth.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients

Arthrospira platensis	**100 mg**
Biotin	**30 microgram**
Calcium citrate	**94.79 mg**
Calcium pantothenate	**5 mg**
Cholecalciferol	**15 microgram**
Chromium picolinate	**241 microgram**
Copper gluconate	**9.286 mg**
Cyanocobalamin	**2.6 microgram**
d-alpha-Tocopherol	**7 mg**
Dunaliella salina	**150 mg**
Fish oil - natural	**500 mg**
Folic acid	**500 microgram**
Iron amino acid chelate	**25 mg**
Magnesium amino acid chelate	**100 mg**
Molybdenum trioxide	**75 microgram**
Nicotinamide	**18 mg**
Phytomenadione	**60 microgram**
Potassium iodide	**327 microgram**
Pyridoxine hydrochloride	**50 mg**
Riboflavin	**1.4 mg**
Selenomethionine	**161.5 microgram**
Sodium ascorbate	**67.5 mg**
Thiamine nitrate	**1.4 mg**
Vitis vinifera	**7.46 mg**
Equivalent: Vitis vinifera (Dry)	895.2 mg
Zinc amino acid chelate	**55 mg**

Public Summary

Summary for ARTG Entry: 174630 Swisse Ultiboost High Strength Wild Fish Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	7/08/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost High Strength Wild Fish Oil

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May help reduce joint inflammation associated with arthritis.,

May help increase joint mobility associated with arthritis.,

Symptomatic relief of osteoarthritis. [Warning S required],

May assist in the management of osteoarthritis. [Warning S required]

Specific Indications

Wild fish from sustainable sources.
Ultiboost Range is based on over 25 years of research.
Swisse Ultiboost High Strength Wild Fish Oil is free from high levels of environmental toxins found in some sources of farmed fish.
Studies show that fish oils help to maintain general good health and are especially beneficial for the heart, brain, joints and eyes.
Omega-3 fatty acids play an important role in helping to maintain a healthy cardiovascular system, healthy blood pressure and support heart health.
Helps to reduce triglycerides in healthy people and maintain healthy cholesterol levels.
Omega-3 fatty acids provide an anti-inflammatory action and may help to reduce inflammation and joint swelling associated with arthritis.
Contains DHA, needed for the maintenance of normal function of the eye, brain and nervous system
DHA is the predominant fatty acid in the central nervous system which is found in the walls of brain cells
contains 50% more omega-3s than regular 1000mg fish oil.

Additional Product Information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Fish oil - natural	**1.5 g**

Public Summary

Summary for ARTG Entry: 174635 Swisse Ultiboost Cranberry

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	7/08/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Cranberry

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If pain or irritation persists for more than 48 hours, consult your doctor. The presence of blood in the urine warrants immediate medical attention (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

Discourages adherence of bacteria to the urinary tract
Helps to maintain urinary tract health.
May help reduce the frequency of recurrent cystitis.
Cranberries are a rich source of antioxidants and possess unique anti-adhesion qualities that protect the urinary tract against the bacteria that causes cystitis.
Swisse Ultiboost Cranberry can help with cystitis symptoms and may help reduce the recurrence of cystitis
Swisse Ultiboost Cranberry contains PACran®, a premium quality cranberry extract to support urinary tract health and help reduce the occurence of cystitis
PACran® is a clinically proven, standardised high potency cranberry extract and is a unique combination of the whole cranberry (not just the juice).
Based on 25+ years research
You'll feel better on Swisse

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral

Visual Identification

Active Ingredients

Vaccinium macrocarpon	**350 mg**
Equivalent: Vaccinium macrocarpon (Fresh)	17.5 g

Public Summary

Summary for ARTG Entry: 174628 Swisse Ultiboost Cold Sore Combat

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	7/08/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

Products

1. Swisse Ultiboost Cold Sore Combat

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Not recommended for use by pregnant and lactating women (or words to that effect).

Standard Indications

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).,

For vitamin (may state the vitamin) supplementation.,

Relief of the symptoms of cold sores. [Warning S required]

Specific Indications

Relief of the symptoms of cold sores.
Helps reduce/prevent the number/frequency of outbreaks of cold sores and reduces healing time of lesions.
Relieves the severity of symptoms of cold sores such as itching, burning and pain.
Vitamin C and zinc for the healing of lesions and healthy skin.
Vitamin C is essential for collagen formation and helps maintain the integrity of connective tissue and skin.
Cold sore relief
Helps to support immune function in normal healthy individuals.
Vitamin C has antioxidant properties, it helps to minimise the risk
of cell damage attributed to free radicals.
Supplementation of Vitamin C is recommended where dietary intake is inadequate and in particular in the elderly.
Andrographis is an Ayurvedic herb that has been used traditionally to help maintain a healthy immune system
As a supplement of Lysine.

Additional Product information

Pack Size/Poison information

Pack Size	**Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Andrographis paniculata	**21.05 mg**
Equivalent: Andrographis paniculata (Dry)	400 mg
Ascorbic acid	**250 mg**
Lysine hydrochloride	**625 mg**
Zinc amino acid chelate	**50 mg**

Public Summary

Summary for ARTG Entry: 174619 Swisse Ultiboost Liquid Iron

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	7/08/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Liquid Iron

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Drink plenty of water (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea [or words to that effect].,

Not for the treatment of iron deficiency conditions (or words to that effect).

Standard Indications

Source of iron. Can assist in maintaining normal blood. Blood tonic.,

Source of iron. Iron is necessary for the formation of haemoglobin which transports oxygen to the tissues.,

May assist in the management of dietary iron deficiency.,

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).

Specific Indications

Aids, assists or helps in the maintenance or improvement of general well-being and energy levels.
All natural flavours, colours and sweeteners.
Sweetened with xylitol, shown to be good for teeth health.
No artificial additives.
A source of iron for those with diets lacking in iron.
A source of iron for those who may have higher requirements such as vegetarians, pregnant and breastfeeding women.
Contains vitamin C which assists in the absorption of iron.
contains B vitamins to help support energy levels.
Contains herbs to help support general health and provide antioxidant support.
Iron is an integral part of haemoglobin, an essential component of red blood cells, which transports oxygen around the body.
Uses Sunative Iron, an encapsulated form of ferric pyrophosphate
Studies have shown GIT symptoms such as constipation and the irritant and astringent action of iron are due to the "local action of iron". Gentle on the stomach.
Sunactive iron is microencapsulated, this may help to reduce this local action and therefore GIT side effects. It also helps to increase absorption and

bioavailability.
Microencapsulation may help to slow release of iron molecules and therefore reduce the dose-related side effects such as constipation.
Microencapsulation also helps to reduce any unpleasant taste when incorporated into a liquid formula.
Based on 25 years of research.
Provides supplementary iron support during pregnancy and breastfeeding and when the body requires increased levels of iron.
Suitable for children.

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Child resistant closure	Not recorded

Pack Size/Poison Information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form	Oral Liquid, suspension
Route of Administration	Oral
Visual Identification	

Active Ingredients

Ascorbic acid	**1 mg/mL**
Cucurbita pepo	**25 microgram/mL**
Equivalent: Cucurbita pepo (Dry)	500 microgram/mL
Cyanocobalamin	**60 microgram/mL**
Ferric pyrophosphate	**3.325 mg/mL**
Fucus vesiculosus	**100 microgram/mL**
Equivalent: Fucus vesiculosus (Dry)	500 microgram/mL
Hibiscus sabdariffa	**200 microgram/mL**
Equivalent: Hibiscus sabdariffa (Dry)	500 microgram/mL
Hippophae rhamnoides	**100 microgram/mL**
Equivalent: Hippophae rhamnoides (Juice fresh)	1.5 mg/mL
Malpighia glabra	**150 microgram/mL**
Equivalent: Malpighia glabra (Dry)	600 microgram/mL
Prunus avium	**5 microgram/mL**
Equivalent: Prunus avium (Dry)	500 microgram/mL
Punica granatum	**10 microgram/mL**
Equivalent: Punica granatum (Dry)	500 microgram/mL
Pyridoxine hydrochloride	**48.62 microgram/mL**
Riboflavin sodium phosphate	**137 microgram/mL**
Rosa canina	**100 microgram/mL**
Equivalent: Rosa canina (Dry)	600 microgram/mL
Silybum marianum	**25 microgram/mL**
Equivalent: Silybum marianum (Dry)	1.75 mg/mL
Spinacia oleracea	**500 microgram/mL**
Stellaria media	**100 microgram/mL**
Equivalent: Stellaria media (Dry)	400 microgram/mL
Thiamine hydrochloride	**123 microgram/mL**
Urtica dioica	**100 microgram/mL**
Equivalent: Urtica dioica (Dry)	500 microgram/mL
Withania somnifera	**100 microgram/mL**
Equivalent: Withania somnifera (Dry)	500 microgram/mL
Zingiber officinale	**25 microgram/mL**
Equivalent: Zingiber officinale (Dry)	500 microgram/mL

Public Summary

Summary for ARTG Entry: 165267 Swisse Ultiboost Sleep

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	15/09/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Sleep

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Relief of sleeplessness. [Warning S required],

Aids, assists or helps in the maintenance or improvement of general well-being.,

Helps relieve nervous tension, stress and mild anxiety. [Warning S required],

Help reduce effects of mild anxiety and nervous tension. [Warning S required]

Specific Indications

Swisse Ultiboost SLEEP is based on the assessment of clinical studies and contains scientifically validated ingredients shown to assist you to sleep like a baby and wake up refreshed.
Swisse Ultiboost SLEEP is a combination of herbs clinically proven to promote calmness and relaxation, The scientifically validated ingredients in Swisse Ultiboost Sleep promote calmness and relaxation, assist in relieving nervous tension and promote natural, restful sleep.
Swisse Ultiboost Sleep is a combination of relaxing and sedative herbs - some used traditionally in Chinese medicine for several thousand years such as anemarrhena, poria cocos and licorice. These traditional herbs help to support the nervous system and the actions of main ingredients valerian and hops. Valerian has been shown to help decrease sleep latency (the time taken to fall asleep) and assist with minimising sleep challenges.
The anti-stress mineral, magnesium is also included as it works to relax both skeletal and smooth muscles - it is often used to help reduce muscle cramps. China root is also included for its assistance with nervous system disturbances such as insomnia.
The natural ingredients included in Swisse Ultiboost Sleep are not addictive and will not disrupt REM sleep and cause morning grogginess the next day like some sleeping tablets may. REM sleep is the time during which you dream and is considered vital for mental health. Disturbance of REM sleep can lead to problems with concentration and memory as well as impaired learning.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Anemarrhena asphodeloides	**10 mg**
Equivalent: Anemarrhena asphodeloides (Dry)	50 mg
Glycyrrhiza glabra	**12.5 mg**
Equivalent: Glycyrrhiza glabra (Dry)	50 mg
Humulus lupulus	**26.67 mg**
Equivalent: Humulus lupulus (Dry)	200 mg
Magnesium orotate	**100 mg**
Poria cocos	**10 mg**
Equivalent: Poria cocos (Dry)	50 mg
Valeriana officinalis	**325 mg**
Equivalent: Valeriana officinalis (Dry)	1.3 g

Public Summary

Summary for ARTG Entry: 164560 Swisse Ultiboost Wild Salmon Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	24/08/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Wild Salmon Oil

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May help reduce joint inflammation associated with arthritis.,

May help reduce joint swelling associated with arthritis.,

May help increase joint mobility associated with arthritis.,

Temporary relief of the pain of osteoarthritis (or) Temporary relief of osteoarthritic pain. [Warning S required],

Symptomatic relief of osteoarthritis. [Warning S required],

May assist in the management of osteoarthritis. [Warning S required]

Specific Indications

Swisse Ultiboost Wild Salmon Oil is based on 25 years of research and contains premium quality omega-3 fatty acids, DHA and EPA. It is one of the only fish oils in the world that is sourced from wild Alaskan salmon that swim freely in the pristine waters of the Arctic Ocean - `sustainable free range fish?.
Swisse Ultiboost Wild Salmon Oil is free from high levels of environmental toxins found in some farmed fish. Swisse?s wild salmon oil is extracted using gravity and a low heat process, similar to the extraction process of virgin olive oil. This process ensures that vitamin E in its natural form, d-alpha tocopherol, is used for its antioxidant properties.
To assist in maintaining a healthy cardiovascular system, healthy skin and triglyceride levels.
May reduce swelling associated with osteoarthritis and arthritis
Omega-3 fatty acids may be beneficial for joint health. In particular EPA may help maintain cartilage health and collagen production.
Natural vitamin E (d-alpha tocopherol) has strong antioxidant properties and unlike synthetic vitamin E, is easily recognised by the body to ensure high bioavailability.
It has been shown that omega-3 fatty acids may play an important role in helping to maintain a healthy cardiovascular system by promoting circulation, healthy blood pressure and cholesterol levels in healthy individuals.
DHA is the predominant fatty acid in the central nervous system which is found in the walls of brain cells and is important for the natural repair process.
The body's highest concentrations of DHA are found in the photoreceptor cells of the retina, which help convert light into neural signals to make sense of what the eye is seeing.
Swisse Ultiboost wild salmon oil will help to support the required daily levels of omega-3 that may be lacking due to insufficient intake from the diet.
EPA is important for the maintenance and development of optimal brain function and cell signalling (the process of communication between nerve cells).
Omega-3 fatty acids may help support bone health by influencing bone cell activity and reducing joint inflammation.

Additional Product Information

Pack Size/Poison Information

Pack Size	Poison Schedule

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients

Fish oil - natural	**1000 mg**

Public Summary

Summary for ARTG Entry: 160963 Swisse Ultiboost Eye

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	8/04/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Eye

Product Type Single Medicine Product **Effective date** 10/12/2009 10:39:18 AM

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Eyes formula. Assists visual fatigue and eye-strain.,

Aids, assists or helps in the maintenance or improvement of general well-being.,

Maintenance of healthy eyes.,

Eyes formula. Helps eyes to adapt to variations in light intensity.,

Eyes formula. Support of healthy eye function.

Specific Indications

Swisse Ultiboost EYE is based on 25 years of research and contains scientifically validated ingredients to assist in providing relief from visual fatigue and eye strain. Swisse Ultiboost EYE is based on the assessment of clinical studies that show certain ingredients in the formula can assist in promoting healthy vision. Swisse Ultiboost EYE is recommended for people who experience problems with night vision and those sensitive to glare. Used as directed, Swisse Ultiboost EYE may deliver positive results relatively quickly.
If you suffer from any medical conditions, please consult your health care professional for advice on the suitability of this product for you. Use only as directed and see your health care professional if symptoms persist

Additional Product information

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Calcium ascorbate	**250 mg**
Cupric sulfate pentahydrate	**3.93 mg**
d-alpha-Tocopheryl acid succinate	**165.2928 mg**
Tagetes erecta	**60 mg**
Equivalent: Tagetes erecta (Dry)	330 mg
Tocopherols concentrate - mixed (low-alpha type)	**378 microgram**
Zinc oxide	**24.89 mg**

Public Summary

Summary for ARTG Entry: 164154 Swisse Ultiboost Odourless Fish Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	6/08/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Odourless Fish Oil

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Temporary relief of the pain of arthritis. (or) Temporary relief of arthritic pain. [Warning S required],

May help increase joint mobility associated with arthritis.,

May help reduce joint swelling associated with arthritis.,

May help reduce joint inflammation associated with arthritis.

Specific Indications

Odourless Fish Oil
Wild fish from sustainable sources.
Assists in maintaining a healthy cardiovascular system, health skin and triglyceride levels.
BASED ON OVER 25 YEARS OF RESEARCH
Swisse Ultiboost products are based on the assessment of clinical studies and incorporate highest grade, scientifically validated ingredients which have been proven to deliver results.
Benefits: Swisse Ultiboost Odourless Fish Oil is based on 25 years of research and contains premium quality omega-3 fatty acids, DHA and EPA. It is one of the only fish oils that is sourced from wild fish that swim freely in the pristine waters of the Pacific Ocean ? our version of `sustainable free range fish?. Swisse Ultiboost Odourless Fish Oil is free from high levels of environmental toxins found in some sources of farmed fish.
Studies show that fish oils help to maintain general good health and are especially beneficial for the heart, brain, joints and eyes.
It has been shown that Omega-3 fatty acids may play an important role in helping to maintain a healthy cardiovascular system by promoting circulation and healthy blood pressure and cholesterol levels. Omega-3 fatty acids may also help support bone health by influencing bone cell activity and reducing joint inflammation.
DHA is the predominant fatty acid in the central nervous system which is found in the walls of brain cells and is important for the natural repair process.
Omega-3 fatty acids may be beneficial for joint health. In particular EPA may help maintain cartilage health and collagen production.
Does not contain artificial chemicals such as polysorbate to reduce the reflux action and fishy after taste.
Swisse Vitamins have launched an advanced new odourless fish oil supplement that delivers premium quality omega-3 fatty acids, DHA and EPA.
Swisse Ultiboost Odourless Fish Oil capsules contain natural spearmint oil and vanilla flavour to ensure no `fishy? after taste.
Omega-3 fatty acids are vital for vision and play a structural and functional role in the retinal and nerve cells of the eye. The body?s highest concentrations of DHA are found in the photoreceptor cells of the retina, which help convert light into neural signals to make sense of what the eye is seeing.

- The fatty acids from the fish oil are important structural components of the phospholipids membranes of cells thoughout the body

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form Capsule, soft

Route of Administration Oral

Visual Identification

Active Ingredients

Fish oil - natural 1000 mg

Public Summary

Summary for ARTG Entry: 160943 Swisse Ultiboost Executive Focus

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	8/04/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27). This condition does not apply to powdered or dried leaf.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Executive Focus

Product Type Single Medicine Product **Effective date** 23/06/2010 10:13:13 AM

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids or assists in the maintenance of peripheral circulation.

Specific Indications

Swisse Ultiboost EXECUTIVE FOCUS is based on 25 years of research and contains scientifically validated ingredients to assist in memory function and stamina. Swisse Ultiboost EXECUTIVE FOCUS is based on the assessment of clinical studies that show certain ingredients in the formula can improve short-term memory, enhance mental alertness, help to relieve anxiety and stress. Swisse Ultiboost EXECUTIVE FOCUS helps to improve brain functions such as learning and concentration. Used as directed, Swisse Ultiboost EXECUTIVE FOCUS may deliver positive results relatively quickly.
If you suffer from any medical conditions, please consult your health care professional for advice on the suitability of this product for you. Use only as directed and see your health care professional if symptoms persist.
Vitamin supplements should not replace a balanced diet.

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Bacopa monnieri	**3.5 g**
Calcium pantothenate	**70 microgram**
Cyanocobalamin	**25 microgram**
Ginkgo biloba	**60 mg**
Equivalent: Ginkgo biloba (Dry)	3 g
Nicotinamide	**20 mg**
Pyridoxine hydrochloride	**25 mg**
Riboflavin	**35 mg**
Thiamine	**25 mg**

Public Summary

Summary for ARTG Entry: 160942 Swisse Ultiboost Heart

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	8/04/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Where the medicine is a conventional release folic acid supplement preparation, in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the responsibility of manufacturers to develop and validate the analytical methods for the determination of folic acid that should be used in conjunction with the USP24 dissolution criteria. This condition does not apply to chewable, effervescent or dispersible tablets or sustained release tablets.

Products

1. Swisse Ultiboost Heart

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Do not take while on warfarin therapy without medical advice.

Standard Indications

Protects capillaries.,

Maintain health of capillaries.,

Aids, assists or helps in the maintenance or improvement of general well-being.,

May assist blood circulation.

Specific Indications

- Support for Healthy Heart & Cholesterol - Swisse Ultiboost HEART has been developed by a professor and contains scientifically validated ingredients that help maintain a healthy cardiovascular system. Ultiboost HEART assists in the maintenance of healthy heart tissue and function as well as protecting capillaries and helping maintain normal blood circulation. Ultiboost HEART also assists in the maintenance of healthy cholesterol level, which is so important for the overall wellbeing of the cardiovascular system.Ultiboost HEART may deliver positive results relatively quickly.For better results: Ultiboost HEART may be effective when used on it's own, however we recommend you use this product in conjunction with Swisse Women's or Men's

Ultivite which act as a "foundation" to provide the body with the important nutrients necessary for general well being. Has antioxidant action via its free radical scavenging properties.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Calcium ascorbate	**499.13 mg**
Cholecalciferol	**.025 mg**
Cyanocobalamin	**200 microgram**
Folic acid	**500 microgram**
Pyridoxine hydrochloride	**25.77 mg**
Selenomethionine	**62.1 microgram**
Ubidecarenone	**9 mg**

Public Summary

Summary for ARTG Entry: 164144 Swisse Ultiboost Vitamin C

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	6/08/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Vitamin C

Product Type Single Medicine Product **Effective date** 28/08/2009 9:44:39 AM

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).,

Do not take while on warfarin therapy without medical advice.,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May help reduce the severity of the symptoms of colds.]Warnings S and COLD required],

May reduce the severity and duration of colds. [Warning COLD required]

Specific Indications

Swisse Ultiboost products are based on the assessment of clinical studies and incorporate highest grade, scientifically validated ingredients which have been proven to deliver results.
Benefits Swisse Ultiboost Vitamin C is based on 25 years of research and contains scientifically validated ingredients to help reduce the severity and duration of colds and support the body?s normal resistance to colds and flu. Vitamin C is a potent antioxidant which can help reduce the risk of cell damage from free radicals. Vitamin C also helps to enhance the absorption of dietary iron and may help promote skin health and wound healing because of its involvement in the manufacture of collagen.
Swisse Ultiboost Vitamin C is derived from non acidic calcium ascorbate making it gentle on the stomach.
-antioxidant, helps to reduce free radical damage
-may help to boost your immune system
-traditionally, vitamin c may help to reduce histamine levels, helping in the management of some allergies
- vitamin c may help improve normal, healthy immune function
- vitamin c is water soluble and is not stored in the body, therefore regular/daily intake is desirable

Additional Product Information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions

Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral

Visual Identification

Active Ingredients

Calcium ascorbate dihydrate	**1.249 g**
Ubidecarenone	**.999 mg**

Public Summary

Summary for ARTG Entry: 163780 Swisse Ultiboost Fish Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	27/07/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Fish Oil

Product Type Single Medicine Product **Effective date** 10/12/2009 10:39:18 AM

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May assist in the management of mood swings. [Warning S required],

May help reduce joint swelling associated with arthritis.,

May help reduce joint inflammation associated with arthritis.,

May help increase joint mobility associated with arthritis.,

Temporary relief of the pain of osteoarthritis (or) Temporary relief of osteoarthritic pain. [Warning S required],

Symptomatic relief of osteoarthritis. [Warning S required],

May assist in the management of osteoarthritis. [Warning S required]

Specific Indications

Swisse Ultiboost FISH OIL is extracted using a low heat process, similar to the extraction process of virgin COLD-PRESSED olive oil, to decrease degradation that can occur during heated extraction methods.
To assist in maintaining a healthy cardiovascular system, healthy skin and triglyceride levels.
May reduce swelling associated with osteoarthritis and arthritis

,

May help to maintain healthy triglyceride levels
Many help to maintain health blood pressure
May help to maintain cardiovascular health

Additional Product Information

Pack Size/Poison Information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients

Alpha tocopherol	**33.56 mg**
Fish oil - natural	**1000 mg**

Public Summary

Summary for ARTG Entry: 160944 Swisse Ultiboost Hair Skin Nails

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	8/04/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Hair Skin Nails

Product Type Single Medicine Product **Effective date** 29/06/2012

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

Not for the treatment of iron deficiency conditions (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

Standard Indications

Formula to support the liver.

Specific Indications

Swisse Ultiboost Hair Skin Nails is a formula containing scientifically validated ingredients, based on clinical studies, which nourish and protect from the inside and provide essential nutrients to support the building blocks of hair, skin and nails, as well as maintaining their health and appearance. This formulation may help to relieve brittle and thinning hair and weak, splitting nails.
Swisse Ultiboost Hair Skin Nails works by delivering nourishment via the bloodstream to the skin, hair follicles and nail beds. This is an internal systemic delivery system that works to support the topical applications such as moisturising creams or conditioners.
Swisse Ultiboost Hair Skin Nails is a comprehensive formula containing biotin which is essential to help strengthen soft, brittle nails and reduce breaking and splitting. Clinical studies have shown biotin to increase nail thickness by up to 25 percent when taken over a 12 week period at the dosage included in Swisse Ultiboost Hair Skin Nails.
Silica is also included for the formation of collagen. Collagen provides a structural framework for the skin by supporting its thickness and integrity. Zinc also assists with collagen production and is particularly important for wound healing. It has also been shown to assist in minimising skin blemishes.
St. Mary's Thistle is a unique inclusion in Swisse Ultiboost Hair Skin Nails. This potent antioxidant has been used traditionally for thousands of years as a 'Spring Tonic' and detoxifier and current clinical studies support its use in liver conditions and for liver cell regeneration. It can help improve skin appearance and reduce blemishes via its detoxification action on the liver.
By providing the body with the key nutrients in Swisse Ultiboost Hair Skin Nails which have a proven role in maintaining the health of skin, hair and nails ? the body will be nourished from the inside which will in turn be reflected on the outside.

Additional Product Information

Pack Size/Poison Information

Pack Size	**Poison Schedule**
Components	
1. Formulation 1	
Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Biotin	**2.6 mg**
Calcium ascorbate	**60.52 mg**
Ferrous fumarate	**16.01 mg**
Silica - colloidal anhydrous	**85.56 mg**
Silybum marianum	**14.29 mg**
Zinc gluconate	**229.7 mg**

Public Summary

Summary for ARTG Entry: 167270 Swisse Women's Ultivite Multi-Vitamin, Mineral and Anti-Oxidant with Herbs Formula 2

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	2/12/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27). This condition does not apply to powdered or dried leaf.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

Where the medicine is a conventional release folic acid/supplement preparation, in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the responsibility of manufacturers to develop and validate the analytical methods for the determination of folic acid that should be used in conjunction with the USP24 dissolution criteria. This condition does not apply to chewable, effervescent or dispersible tablets or sustained release tablets.

Products

1. Swisse Women's Ultivite Multi-Vitamin, Mineral and Anti-Oxidant with Herbs Formula 2

Product Type Single Medicine Product **Effective date** 31/05/2011 12:08:48 PM

Warnings

Do not take while on warfarin therapy without medical advice.,

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

WARNING - When taken in excess of 3000 micrograms retinol equivalents, vitamin A can cause birth defects.,

If you are pregnant, or considering becoming pregnant, do not take vitamin A supplements without consulting your doctor or pharmacist.,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].,

Contains lactose (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

For mineral (may state the mineral) supplementation.,

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).,

May assist in the management of dietary folate deficiency.,

Aids, assists or helps in the maintenance or improvement of general well-being.,

For vitamin (may state the vitamin) supplementation.

Specific Indications

Assists in supporting a healthy cardiovascular system
contains antioxidants to assist in decreasing the risk of cell damage from free radicals.
Assists in maintaining a healthy and normal immune system.

Additional Product Information

Pack Size/Poison Information

Pack Size | **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Bifidobacterium longum	**0 mg**
Biotin	**200 microgram**
Calcium ascorbate dihydrate	**200 mg**
Calcium orotate	**30 mg**
Calcium pantothenate	**55 mg**
Cholecalciferol	**0125 microgram**
Choline bitartrate	**15 mg**
Chromium picolinate	**402 microgram**
Cinnamomum cassia	**6.67 mg**
Equivalent: Cinnamomum cassia (Dry)	100 mg
Citrus bioflavonoids extract	**20 mg**
Copper gluconate	**14.29 mg**
Crataegus monogyna	**12.5 mg**
Equivalent: Crataegus monogyna (Dry)	50 mg
Cyanocobalamin	**120 microgram**
Cynara scolymus	**12.5 mg**
Equivalent: Cynara scolymus (Fresh)	50 mg
d-alpha-Tocopheryl acid succinate	**20 mg**
Folic acid	**500 microgram**
Ginkgo biloba	**20 mg**
Equivalent: Ginkgo biloba (Dry)	1 g
Gymnema sylvestre	**6.25 mg**
Inositol	**15 mg**
Lactobacillus helveticus	**0 mg**
Lactobacillus rhamnosus	**0 mg**
Magnesium aspartate dihydrate	**110 mg**
Manganese amino acid chelate	**40 mg**
Molybdenum trioxide	**67.5 microgram**
Nicotinamide	**50 mg**
Phytomenadione	**60 microgram**
Potassium iodide	**52.32 microgram**
Pyridoxine hydrochloride	**30 mg**
Retinyl acetate	**142.5712 microgram**
Riboflavin	**30 mg**
Selenomethionine	**65 microgram**
Silybum marianum	**14.29 mg**
Equivalent: Silybum marianum (Dry)	1 g
Spearmint Oil	**2 mg**
Thiamine hydrochloride	**55 mg**

Trigonella foenum-graecum	**150 mg**
Equivalent: Trigonella foenum-graecum (Dry)	18.75 g
Ubidecarenone	**1.0005 mg**
Urtica dioica	**20 mg**
Equivalent: Urtica dioica (Dry)	100 mg
Vaccinium macrocarpon	**20 mg**
Equivalent: Vaccinium macrocarpon (Fresh)	1000 mg
Vaccinium myrtillus	**2 mg**
Vitis vinifera	**8.33 mg**
Equivalent: Vitis vinifera (Dry)	1 g
Withania somnifera	**20 mg**
Equivalent: Withania somnifera (Dry)	200 mg
Zinc amino acid chelate	**85 mg**

Public Summary

Summary for ARTG Entry: 168780 Swisse Ultiboost Calcium + D

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	4/02/2010
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Calcium + D

Product Type Single Medicine Product **Effective date** 3/03/2010 11:14:01 AM

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Source of calcium. Women's calcium requirements are increased after menopause.,

Source of calcium. A calcium supplement formulated to strengthen bone and tissue in growing and mature users. (or) Source of calcium. A calcium supplement formulated to strengthen bone and tissue for children and older adults.,

Source of calcium. Adequate dietary calcium in our youth and throughout life is required to maximise bone.,

Source of calcium. May assist in the prevention and/or treatment of osteoporosis.,

Source of calcium. Women's calcium requirements are increased after menopause. Calcium supplementation may be of assistance in the prevention and/or treatment of osteoporosis.,

Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Specific Indications

Vitamin D3 and calcium supplement for when these vitamins/minerals are lacking in the diet
Vitamin D supplementation may assist in regulation of calcium metbolism and bone mineralization in those not obtaining sufficient vitamin D due to diet or lifestyle factors
Vitamin D promotes the body?s absorption of calcium, important to maintain healthy bones and teeth
A supplement to aid in the management of calcium deficiency states
Helps maintain healthy bones and teeth
Calcium requirements may be increased with age, gender, diet, pregnancy and laction ? provides supplemental calcium
Women?s calcium needs are increased after menopause
Formulated using the citrate form of calcium, shown to have a higher bioavailability than other forms of calcium
Patented black pepper extract (piper nigrum) Bioperine contains active ingredient piperine, shown to help increase nutrient uptake

Additional Product Information

Pack Size/Poison information

Pack Size	**Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Calcium citrate	**1.5797 g**
Cholecalciferol	**.0083 mg**
Piper nigrum	**1.75 mg**
Equivalent: Piper nigrum (Dry)	29.75 mg

Public Summary

Summary for ARTG Entry: 157728 Swisse Ultiboost Pregnancy Fish Oil

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	10/12/2008
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.

Products

1. Swisse Ultiboost Pregnancy Fish Oil

Product Type Single Medicine Product **Effective date** 31/05/2011 12:08:48 PM

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

Rich source of Omega-3 fatty acids which assist in maintaining healthy skin. Helps to assist in the maintenance of normal eye and brain function. It is also high in DHA which is necessary for the normal function of the brain and nervous system. Assists in promoting the health of mother and baby. May assist in relieving symptoms of post natal mood swings.

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	

Active Ingredients

d-alpha-Tocopherol	**33.56 mg**
Fish oil - natural	**1000 mg**

Public Summary

Summary for ARTG Entry: 167269 Swisse Men's Ultivite Multi-Vitamin Mineral & Anti-Oxidant with Herbs Formula 2

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	2/12/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27). This condition does not apply to powdered or dried leaf.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm,as amended from time to time.,

Where the medicine is a conventional release folic acid supplement preparation, in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the responsibility of manufacturers to develop and validate the analytical methods for the determination of folic acid that should be used in conjunction with the USP24 dissolution criteria. This condition does not apply to chewable, effervescent or dispersible tablets or sustained release tablets.

Products

1. Swisse Men's Ultivite Multi-Vitamin Mineral & Anti-Oxidant with Herbs Formula 2

Product Type Single Medicine Product **Effective date** 31/05/2011 12:08:48 PM

Warnings

Contains lactose (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

WARNING - When taken in excess of 3000 micrograms retinol equivalents, vitamin A can cause birth defects.,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

If you are pregnant, or considering becoming pregnant, do not take vitamin A supplements without consulting your doctor or pharmacist.,

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

Do not take while on warfarin therapy without medical advice.

Standard Indications

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).,

For mineral (may state the mineral) supplementation.,

For vitamin (may state the vitamin) supplementation.,

May assist in the management of dietary folate deficiency.,

Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

May assist in supporting a healthy cardiovascular system
Provides support for the nervous system and is beneficial during times of stress.
Contains antioxidants to assist in decreasing the risk of cell damage from free radicals.

Additional Product information

Pack Size/Poison information

Pack Size | **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Bifidobacterium longum	**0 mg**
Biotin	**200 microgram**
Calcium ascorbate dihydrate	**200 mg**
Calcium orotate	**20 mg**
Calcium pantothenate	**60 mg**
Cholecalciferol	**.0125 microgram**
Choline bitartrate	**20 mg**
Chromium picolinate	**402 microgram**
Cinnamomum cassia	**6.67 mg**
Equivalent: Cinnamomum cassia (Dry)	100 mg
Citrus bioflavonoids extract	**100 mg**
Copper gluconate	**21.43 mg**
Crataegus monogyna	**25 mg**
Equivalent: Crataegus monogyna (Dry)	100 mg
Cyanocobalamin	**120 microgram**
Cynara scolymus	**12.5 mg**
Equivalent: Cynara scolymus (Fresh)	50 mg
d-alpha-Tocopheryl acid succinate	**25 mg**
Folic acid	**500 microgram**
Ginkgo biloba	**20 mg**
Equivalent: Ginkgo biloba (Dry)	1000 mg
Gymnema sylvestre	**6.25 mg**
Inositol	**20 mg**
Lactobacillus helveticus	**0 mg**
Lactobacillus rhamnosus	**0 mg**
Magnesium aspartate dihydrate	**110 mg**
Manganese amino acid chelate	**50 mg**
Molybdenum trioxide	**67.5 microgram**
Nicotinamide	**55 mg**
Phytomenadione	**70 microgram**
Potassium iodide	**52.32 microgram**
Pyridoxine hydrochloride	**20 mg**
Retinyl acetate	**.1487 mg**
Riboflavin	**35 mg**
Selenomethionine	**65 microgram**
Serenoa repens	**10 mg**
Equivalent: Serenoa repens (Dry)	100 mg
Silybum marianum	**17.14 mg**
Equivalent: Silybum marianum (Dry)	1.2 g
Spearmint Oil	**2 mg**

Thiamine hydrochloride	**60 mg**
Trigonella foenum-graecum	**150 mg**
Equivalent: Trigonella foenum-graecum (Dry)	18.75 g
Ubidecarenone	**.3 mg**
Urtica dioica	**20 mg**
Equivalent: Urtica dioica (Dry)	100 mg
Vaccinium macrocarpon	**20 mg**
Equivalent: Vaccinium macrocarpon (Juice fresh)	1000 mg
Vaccinium myrtillus	**200 mg**
Vitis vinifera	**8.33 mg**
Equivalent: Vitis vinifera (Dry)	1 g
Zinc amino acid chelate	**100 mg**

Public Summary

Summary for ARTG Entry: 166876 Swisse Ultiboost Eye

ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	17/11/2009
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at http://www.tga.gov.au/industry/cm-colourings-oral-use.htm as amended from time to time.

Products

1. Swisse Ultiboost Eye

Product Type Single Medicine Product **Effective date** 31/05/2011 12:08:48 PM

Warnings

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Eyes formula. Support of healthy eye function.,

Maintenance of healthy eyes.

Specific Indications

Antioxidant supplement, formulated to help maintain healthy eyes and vision.
Contains the herb Marigold (Tagetes erecta, from Xangold, a patented extract of the marigold flower) - a rich source of lutein and zeaxanthin.
High concentrations of lutein and zeaxanthin are found naturally in the eye, particularly the macular area of the retina. They help protect the eye from potentially harmful light, and therefore may help support eye health.
Helps to improve/maintain health of macular region of the eye.
Contains zinc, important for healthy vision. The retina contains one of the highest concentrations of this mineral.
Natural vitamin E and vitamin C further help to reduce free radical damage. Vitamin C is the first line of antioxidant protection in the body and is also responsible for regenerating oxidised vitamin E , enhancing the antioxidant effect of the natural vitamin E.Natural vitamin E is recognised best by the body and therefore has greater benefits than synthetic forms.
Swisse Ultiboost EYE is based on 25 years of research and contains scientifically validated ingredients to assist with eye health. Swisse Ultiboost EYE is based on the assessment of clinical studies that show certain ingredients in the formula can assist in promoting healthy vision.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1. Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Calcium ascorbate	**250 mg**
Cupric sulfate pentahydrate	**3.93 mg**
d-alpha-Tocopheryl acid succinate	**165.2928 mg**
Tagetes erecta	**60 mg**
Equivalent: Tagetes erecta (Dry)	330 mg
Tocopherols concentrate - mixed (low-alpha type)	**378 microgram**
Zinc oxide	**24.89 mg**